DNAtriX, Inc. is a Texas-based biotechnology company focused on the development of an oncoloytic virus platform initially for the treatment of malignant glioma. DNAtriX's lead product, delta24RGD, is a next-generation adenovirus invented by company founder Dr. Juan Fueyo and Dr. Frank McCormick. 

Phase I clinical trials for delta24RGD began in Q4 of 2008.